A rabies vaccine freeze-dried preparation and preparation method thereof
By using lyophilized protective agents prepared with components such as trehalose, sucrose and dextran, combined with alternating microwave treatment and freeze-thaw circulation treatment, the problem of reduced stability and titer during preservation of rabies vaccines is solved, and the problem of further improvement is achieved Efficient freeze-drying protection effect and safety, suitable for industrial production.
Patent Information
- Application Number
- CN202411110266.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-08-14
AI Technical Summary
Existing rabies vaccines face problems of reduced stability and titer during preparation and preservation, especially in environments of changing temperature and humidity, and the use of human albumin in traditional lyophilized protective agents leads to increased costs and safety concerns.
Using trehalose, sucrose and dextran as lyophilized protective agents, lyophilized protective compositions are prepared by alternating microwave treatment and freeze-thaw cycle treatment, combined with phosphate buffer solution to form a mixture of lyophilized protective agent and rabies vaccine stock solution to prepare freeze Dry preparation.
It improves the stability and validity period of the lyophilized preparation of rabies vaccine, avoids the safety risks of the introduction of exogenous ingredients, is suitable for industrial mass production, and shows good lyophilized protection effect and heat resistance stability.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of rabies vaccines, in particular to a rabies vaccine freeze-dried preparation and a preparation method thereof. Background Art
[0002] Rabies is a highly lethal disease caused by the rabies virus. When humans are exposed to the rabies virus, if it is not discovered and treated in time, it will seriously threaten human life. Therefore, the prevention and control of rabies is particularly important. At present, vaccination is the main way to control the occurrence and spread of rabies, especially for people who have long-term contact with sick animals. As a key means of preventing rabies, the stability and effectiveness of rabies vaccines are directly related to the vaccination effect and public health. However, existing rabies vaccines face many challenges in the preparation and preservation process. On the one hand, the preparation process of rabies vaccines has a huge impact on their shelf life and potency. How to ensure that the vaccine maintains high potency and stability during the preparation process is an urgent problem to be solved. On the other hand, rabies vaccines are easily affected by environmental factors such as temperature and humidity during storage and transportation, resulting in reduced vaccine potency or even failure.
[0003] In order to overcome the above technical difficulties and improve the stability and effectiveness of rabies vaccines, researchers are constantly exploring new preparation methods and freeze-drying protection technologies. Freeze-drying technology, as an effective means of vaccine preservation, can significantly extend the shelf life of the vaccine and maintain its potency. However, most of the freeze-dried protective agents for rabies vaccines disclosed in prior arts such as CN115040656A and CN108434106A currently use human albumin, which not only increases the cost of the vaccine, but also may cause safety issues of introducing foreign viruses. Therefore, it is necessary to develop a freeze-dried protective agent with higher cost-effectiveness and better freeze-drying protection effect to replace traditional human albumin, so as to ensure the high efficiency and stability of the rabies vaccine while completely eliminating the safety concerns caused by the introduction of exogenous components. Summary of the invention
[0004] In order to solve the above problems, the present invention provides a rabies vaccine freeze-dried preparation and a preparation method thereof.
[0005] In a first aspect, the present invention provides a rabies vaccine freeze-dried preparation, wherein the rabies vaccine freeze-dried preparation comprises a rabies vaccine stock solution and a freeze-drying protective agent;
[0006] In terms of weight percentage, the lyophilization protective agent includes the following components:
[0007] 6.3-8.4% of freeze-dried protective composition, 0.7-1.1% of chloride salt, and the balance of phosphate buffer;
[0008] The preparation method of the freeze-dried protective composition comprises the following steps:
[0009] Step (1): adding trehalose, sucrose and dextran into deionized water and stirring and mixing, and then performing microwave treatment alternately with a first microwave power and a second microwave power to obtain a first mixed material;
[0010] Step (2): freeze-thaw the first mixture to obtain a second mixture;
[0011] Step (3): the second mixed material is subjected to a cyclic treatment in sequence according to the alternating microwave treatment in step (1) and the freeze-thaw treatment in step (2), the number of cycles being 3 to 10 times, and then dried and crushed to obtain the freeze-dried protective composition;
[0012] The first microwave power is 60-100W, and the second microwave power is 350-400W.
[0013] Further, the step of adding trehalose, sucrose and dextran into deionized water, stirring and mixing, and then performing microwave treatment alternately with a first microwave power and a second microwave power to obtain a first mixed material comprises the following process:
[0014] Trehalose, sucrose and dextran in a weight ratio of (1-2):(1-2):(2-4) are added to deionized water and stirred and mixed, and then microwave-treated 4-8 times alternately with a first microwave power and a second microwave power, each microwave treatment lasting 20-50 seconds, to obtain the first mixture.
[0015] Furthermore, the weight ratio of the trehalose, the sucrose and the dextran is 1:1.5:3, and the weight of the added deionized water accounts for 1 to 2 times the total weight of the trehalose, the sucrose and the dextran.
[0016] Furthermore, the first microwave power is 75W, and the second microwave power is 380W.
[0017] Furthermore, the chloride salt includes at least one of sodium chloride and magnesium chloride.
[0018] Further, the freeze-thaw treatment includes a freezing treatment and a thawing treatment;
[0019] The freezing treatment condition parameters include: first freezing at -50~-40°C for 3~4 hours, then vacuuming to 0.1~0.2 mbar and heating to -25~-20°C for second freezing for 12~18 hours;
[0020] The thawing process condition parameters include: thawing to liquid at a temperature of 35-45°C.
[0021] Furthermore, the volume ratio of the rabies vaccine stock solution to the lyophilization protective agent is 1:(0.8~1.5).
[0022] In a second aspect, the present invention provides a method for preparing a lyophilized rabies vaccine preparation according to any one of the first aspects, the method for preparing the lyophilized rabies vaccine preparation comprising the following steps:
[0023] Mixing the rabies vaccine stock solution and the lyophilization protective agent to obtain a semi-finished product;
[0024] The semi-finished product is freeze-dried to obtain the rabies vaccine freeze-dried preparation.
[0025] Furthermore, the freeze-drying process includes a pre-freezing process, a main drying process and a final drying process in sequence;
[0026] The working condition parameters of the pre-freezing process are the same as the working condition parameters of the first freezing process;
[0027] The working condition parameters of the main drying process are the same as the working condition parameters of the second freezing process.
[0028] Furthermore, the condition parameters of the non-drying treatment include: heat preservation treatment at a temperature of 25° C. for 5 to 8 hours.
[0029] The above technical solution provided by the present invention has at least the following advantages compared with the prior art:
[0030] The present invention provides a rabies vaccine freeze-dried preparation. The present invention utilizes a first microwave power and a second microwave power to perform alternating microwave treatment in combination with a freeze-thaw method to perform cyclic treatment on a freeze-dried protection composition for several times, thereby enhancing the freeze-drying protection effect on the vaccine, so that the prepared rabies vaccine freeze-dried preparation has the characteristics of intact appearance, good stability, etc., thereby extending the validity period of the vaccine, and providing a new means for the preparation of rabies vaccine freeze-dried preparations. DETAILED DESCRIPTION
[0031] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described in combination with the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.
[0033] In a first aspect, the present invention provides a rabies vaccine freeze-dried preparation, wherein the rabies vaccine freeze-dried preparation comprises a rabies vaccine stock solution and a freeze-drying protective agent;
[0034] In terms of weight percentage, the lyophilization protective agent includes the following components:
[0035] 6.3-8.4% of freeze-dried protective composition, 0.7-1.1% of chloride salt, and the balance of phosphate buffer;
[0036] The preparation method of the freeze-dried protective composition comprises the following steps:
[0037] Step (1): adding trehalose, sucrose and dextran into deionized water and stirring and mixing, and then performing microwave treatment alternately with a first microwave power and a second microwave power to obtain a first mixed material;
[0038] Step (2): freeze-thaw the first mixture to obtain a second mixture;
[0039] Step (3): the second mixed material is subjected to a cyclic treatment in sequence according to the alternating microwave treatment in step (1) and the freeze-thaw treatment in step (2), the number of cycles being 3 to 10 times, and then dried and crushed to obtain the freeze-dried protective composition;
[0040] The first microwave power is 60-100W, and the second microwave power is 350-400W.
[0041] The present invention provides a rabies vaccine freeze-dried preparation. The present invention utilizes a first microwave power and a second microwave power to perform alternating microwave treatment in combination with a freeze-thaw method to perform cyclic treatment on a freeze-dried protection composition for several times, thereby enhancing the freeze-drying protection effect on the vaccine, so that the prepared rabies vaccine freeze-dried preparation has the characteristics of intact appearance, good stability, etc., thereby extending the validity period of the vaccine, and providing a new means for the preparation of rabies vaccine freeze-dried preparations.
[0042] The rabies vaccine stock solution in the present invention can be an injectable rabies vaccine or an oral rabies vaccine; a commercially available product can be purchased directly, or it can be prepared by itself according to the prior art disclosed preparation methods such as CN115040656A, CN103877570A, CN114591922A, CN117018177A and the applicant's previous patent application CN103468743A in the background technology. In some specific embodiments, the rabies vaccine stock solution can be prepared according to the methods disclosed in paragraphs 0065 to 0111 of the applicant's previous patent application CN103468743A.
[0043] In some specific embodiments, the immunized subjects of the lyophilized rabies vaccine preparation provided by the present invention can be humans or animals, depending on the actual situation and the selected rabies vaccine stock solution.
[0044] In some specific embodiments, the rabies vaccine freeze-dried preparation includes an oral rabies vaccine freeze-dried preparation and an injectable rabies vaccine freeze-dried preparation. When an oral rabies vaccine freeze-dried preparation is required, the freeze-dried cake of the rabies vaccine freeze-dried preparation can be crushed and filled into capsules, such as Lonza's E44000, or enteric-coated capsules from other suppliers, and sealed for storage. Before use, the capsule is taken out of the wrapped bait and then delivered to the target immune subject (such as a human or an animal). The target immune subject ingests the capsule containing the vaccine to achieve digestion and absorption of the capsule in the intestine, thereby completing the vaccination of the vaccine.
[0045] In some specific embodiments, the pH of the phosphate buffer is 7.0-8.0, and the phosphate buffer can be directly purchased from the market or prepared by the preparation method disclosed in the prior art.
[0046] In some specific embodiments, the step of adding trehalose, sucrose and dextran into deionized water, stirring and mixing, and then performing microwave treatment alternately with a first microwave power and a second microwave power to obtain a first mixture comprises the following process:
[0047] Trehalose, sucrose and dextran in a weight ratio of (1-2):(1-2):(2-4) are added to deionized water and stirred and mixed, and then microwave-treated 4-8 times alternately with a first microwave power and a second microwave power, each microwave treatment lasting 20-50 seconds, to obtain the first mixture.
[0048] In some specific embodiments, the weight ratio of the trehalose, the sucrose and the dextran is 1:1.5:3, and the weight of the added deionized water accounts for 1 to 2 times the total weight of the trehalose, the sucrose and the dextran.
[0049] In some specific embodiments, the first microwave power is 75W, and the second microwave power is 380W.
[0050] In some specific embodiments, the chloride salt includes at least one of sodium chloride and magnesium chloride.
[0051] In some specific embodiments, the freeze-thaw treatment includes a freezing treatment and a thawing treatment;
[0052] The freezing treatment condition parameters include: first freezing at -50~-40°C for 3~4 hours, then vacuuming to 0.1~0.2 mbar and heating to -25~-20°C for second freezing for 12~18 hours;
[0053] The thawing process condition parameters include: thawing to liquid at a temperature of 35-45°C.
[0054] In some specific embodiments, the volume ratio of the rabies vaccine stock solution to the lyophilization protectant is 1:(0.8~1.5).
[0055] In a second aspect, based on the same inventive concept, the present invention provides a method for preparing a lyophilized rabies vaccine preparation according to any one of the first aspects, the method for preparing the lyophilized rabies vaccine preparation comprising the following steps:
[0056] Mixing the rabies vaccine stock solution and the lyophilization protective agent to obtain a semi-finished product;
[0057] The semi-finished product is freeze-dried to obtain the rabies vaccine freeze-dried preparation.
[0058] The preparation method of the rabies vaccine freeze-dried preparation provided by the present invention is simple to operate, does not require additional specific equipment, and is suitable for industrial batch production.
[0059] In some specific embodiments, the freeze-drying process includes a pre-freezing process, a main drying process and a final drying process in sequence;
[0060] The working condition parameters of the pre-freezing process are the same as the working condition parameters of the first freezing process;
[0061] The working condition parameters of the main drying process are the same as the working condition parameters of the second freezing process;
[0062] The condition parameters of the non-drying treatment include: heat preservation treatment at 25° C. for 5 to 8 hours.
[0063] It should be noted that, unless otherwise specified or explained, the component raw materials involved in the rabies vaccine freeze-dried preparation provided by the present invention can be directly commercially available products; the operating steps involved, unless otherwise specified or explained, can be carried out in accordance with the operating methods disclosed in the prior art or using existing equipment and its usage methods.
[0064] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually measured according to national standards. If there is no corresponding national standard, then the conditions recommended by the manufacturer are followed.
[0065] Example 1
[0066] This example provides a lyophilized protective agent, which comprises the following components in terms of weight percentage: 7.1% of the lyophilized protective composition, 0.9% of chloride salt, and the balance of phosphate buffer;
[0067] The chloride salt is sodium chloride;
[0068] The preparation method of the freeze-dried protective composition comprises the following steps:
[0069] Step (1): adding trehalose, sucrose and dextran into deionized water and stirring and mixing them, the stirring speed is 200 rpm, the stirring time is 20 minutes, and then performing microwave treatment alternately with the first microwave power and the second microwave power, the first microwave power treatment and the second microwave power treatment are performed 3 times each, and the microwave treatment is performed 6 times in total, and the time of each microwave treatment is 30 seconds, to obtain the first mixed material; wherein the weight ratio of the trehalose, the sucrose and the dextran is 1:1.5:3, the weight of the added water accounts for 1.5 times the total weight of the trehalose, the sucrose and the dextran, the first microwave power is 75W, and the second microwave power is 380W;
[0070] Step (2): freezing and thawing the first mixed material obtained in step (1) in sequence to obtain a second mixed material; wherein the freezing treatment condition parameters include: first freezing at -45°C for 3.5 hours, then vacuumizing to 0.1 mbar and heating to -25°C for second freezing for 16 hours; and the thawing treatment condition parameters include: thawing at 40°C to liquid;
[0071] Step (3): The second mixed material obtained in step (2) is subjected to a cyclic treatment according to the alternating microwave treatment in step (1) and the freeze-thaw treatment in step (2), the number of cycles being 5 times, and then placed in an oven at 45° C. to dry to constant weight, and the dried solid is crushed and passed through a 100-mesh sieve to obtain the freeze-dried protective composition.
[0072] The preparation method of the above-mentioned lyophilized protective agent comprises the following process: weighing the components of the lyophilized protective agent in proportion and mixing them, and then using a microporous filter membrane with a pore size of 0.22 microns to perform sterilization filtration to obtain the lyophilized protective agent.
[0073] Example 2
[0074] This example provides a lyophilized protective agent, which comprises the following components in terms of weight percentage: 6.3% of the lyophilized protective composition, 0.7% of the chloride salt, and the balance of phosphate buffer;
[0075] The chloride salt is sodium chloride;
[0076] The preparation method of the freeze-dried protective composition comprises the following steps:
[0077] Step (1): adding trehalose, sucrose and dextran into deionized water and stirring and mixing them, the stirring speed is 200 rpm, the stirring time is 20 minutes, and then performing microwave treatment alternately with a first microwave power and a second microwave power, the first microwave power treatment and the second microwave power treatment are performed 3 times each, a total of 6 microwave treatments, and the time of each microwave treatment is 50 seconds, to obtain the first mixed material; wherein the weight ratio of the trehalose, the sucrose and the dextran is 1:2:4, the weight of the added water accounts for 1.5 times the total weight of the trehalose, the sucrose and the dextran, the first microwave power is 60W, and the second microwave power is 350W;
[0078] Step (2): freezing and thawing the first mixed material obtained in step (1) in sequence to obtain a second mixed material; wherein the freezing treatment condition parameters include: first freezing at -45°C for 3.5 hours, then vacuumizing to 0.1 mbar and heating to -25°C for second freezing for 16 hours; and the thawing treatment condition parameters include: thawing at 40°C to liquid;
[0079] Step (3): The second mixed material obtained in step (2) is subjected to a cyclic treatment according to the alternating microwave treatment in step (1) and the freeze-thaw treatment in step (2), the number of cycles being 5 times, and then placed in an oven at 45° C. to dry to constant weight, and the dried solid is crushed and passed through a 100-mesh sieve to obtain the freeze-dried protective composition.
[0080] The preparation method of the above lyophilized protective agent is the same as that in Example 1.
[0081] Example 3
[0082] This example provides a lyophilized protective agent, which comprises the following components in terms of weight percentage: 8.4% of the lyophilized protective composition, 1.1% of the chloride salt, and the balance of phosphate buffer;
[0083] The chloride salt is sodium chloride;
[0084] The preparation method of the freeze-dried protective composition comprises the following steps:
[0085] Step (1): adding trehalose, sucrose and dextran into deionized water and stirring and mixing them, the stirring speed is 200 rpm, the stirring time is 20 minutes, and then performing microwave treatment alternately with a first microwave power and a second microwave power, the first microwave power treatment is performed 3 times each, and the microwave treatment is performed 6 times in total, and the time of each microwave treatment is 20 seconds, to obtain the first mixed material; wherein the weight ratio of the trehalose, the sucrose and the dextran is 2:1:4, the weight of the added water accounts for 1.5 times the total weight of the trehalose, the sucrose and the dextran, the first microwave power is 100 W, and the second microwave power is 400 W;
[0086] Step (2): freezing and thawing the first mixed material obtained in step (1) in sequence to obtain a second mixed material; wherein the freezing treatment condition parameters include: first freezing at -45°C for 3.5 hours, then vacuumizing to 0.1 mbar and heating to -25°C for second freezing for 16 hours; and the thawing treatment condition parameters include: thawing at 40°C to liquid;
[0087] Step (3): The second mixed material obtained in step (2) is subjected to a cyclic treatment according to the alternating microwave treatment in step (1) and the freeze-thaw treatment in step (2), the number of cycles being 5 times, and then placed in an oven at 45° C. to dry to constant weight, and the dried solid is crushed and passed through a 100-mesh sieve to obtain the freeze-dried protective composition.
[0088] The preparation method of the above lyophilized protective agent is the same as that in Example 1.
[0089] Example 4
[0090] This example provides a rabies vaccine freeze-dried preparation, and the preparation method of the rabies vaccine freeze-dried preparation comprises the following steps:
[0091] Step (1): mixing the rabies vaccine stock solution and the lyophilized protective agent described in Example 1 in a volume ratio of 1:1.2 to obtain a semi-finished product;
[0092] Step (2): the semi-finished product obtained in step (1) is subjected to pre-freezing treatment, main drying treatment and final drying treatment in sequence to obtain the rabies vaccine freeze-dried preparation;
[0093] The working condition parameters of the pre-freezing treatment include: pre-freezing treatment at -45°C for 3.5 hours;
[0094] The working condition parameters of the main drying process include: vacuuming to 0.1 mbar and heating to -25°C for main drying for 16 hours;
[0095] The condition parameters of the non-drying treatment include: heat preservation treatment at 25° C. for 6 hours.
[0096] Example 5
[0097] This example provides a rabies vaccine freeze-dried preparation and a preparation method thereof, which is different from Example 4 only in that the freeze-dried protective agent is obtained from Example 2; the remaining steps and parameters are the same.
[0098] Example 6
[0099] This example provides a rabies vaccine freeze-dried preparation and a preparation method thereof, which is different from Example 4 only in that the freeze-dried protective agent is obtained from Example 3; the remaining steps and parameters are the same.
[0100] Comparative Example 1
[0101] This example provides a lyophilized protective agent and a preparation method thereof, which is different from Example 1 only in that microwave alternating treatment and freeze-thaw treatment are not performed during the preparation of the lyophilized protective composition.
[0102] The lyophilization protective agent comprises the following components in weight percentage: 7.1% of lyophilization protective composition, 0.9% of chloride salt, and the balance of phosphate buffer;
[0103] The chloride salt is sodium chloride;
[0104] The preparation method of the freeze-dried protective composition comprises the following steps:
[0105] Step (1): adding trehalose, sucrose and dextran into deionized water and stirring and mixing them at a stirring speed of 200 rpm for 20 minutes to obtain the first mixture; wherein the weight ratio of the trehalose, the sucrose and the dextran is 1:1.5:3, and the weight of the added water accounts for 1.5 times the total weight of the trehalose, the sucrose and the dextran;
[0106] Step (2): The first mixed material obtained in step (1) is placed in an oven at 45° C. to be dried to a constant weight and the dried solid is crushed and passed through a 100-mesh sieve to obtain the freeze-dried protective composition.
[0107] The preparation method of the above-mentioned lyophilized protective agent comprises the following process: weighing the components of the lyophilized protective agent in proportion and mixing them, and then using a microporous filter membrane with a pore size of 0.22 microns to perform sterilization filtration to obtain the lyophilized protective agent.
[0108] Comparative Example 2
[0109] This example provides a lyophilized protective agent and a preparation method thereof, which is different from Example 1 only in that the first microwave power and the second microwave power are both 600 W; the remaining steps and parameters are the same.
[0110] Comparative Example 3
[0111] This example provides a rabies vaccine freeze-dried preparation and a preparation method thereof, which is different from Example 4 only in that the freeze-dried protective agent is obtained from Comparative Example 1; the remaining steps and parameters are the same.
[0112] Comparative Example 4
[0113] This example provides a rabies vaccine freeze-dried preparation and a preparation method thereof, which is different from Example 4 only in that the freeze-dried protective agent is obtained from Comparative Example 2; the remaining steps and parameters are the same.
[0114] Test Case
[0115] In this example, the freeze-dried protection effect of the rabies vaccine freeze-dried preparations obtained in Examples 4 to 6 and Comparative Examples 3 to 4 was tested.
[0116] Test method: The rabies vaccine freeze-dried preparation samples were stored at 5°C for 12 months and at 37°C for 28 days, and the potency was tested before and after freeze-drying according to the 3503 method of the General Rules of Part III of the 2015 edition of the Chinese Pharmacopoeia; and the first potency decrease rate was calculated according to Formula 1, and the higher the first potency decrease rate, the worse the long-term stability of freeze-drying; the second potency decrease rate of the vaccine was calculated according to Formula 2, and the higher the second potency decrease rate, the worse the heat stability; wherein, Formula 1: First potency decrease rate (%) = (E1-E2) / E1×100, E1 is the potency before freeze-drying, and E2 is the potency after storage at 5°C for 12 months; Formula 2: Second potency decrease rate (%) = (E1-E3) / E1×100%, E1 is the potency before freeze-drying, and E3 is the potency after storage at 37°C for 28 days.
[0117] The test results are shown in Table 1.
[0118] Table 1
[0119]
[0120] As shown in Table 1, compared with the comparative example, the lyophilized rabies vaccine preparation provided in the embodiment of the present invention has better long-term lyophilization stability and heat resistance stability, and the lyophilized rabies vaccine preparation provided in Example 1 has the best lyophilization protection effect. In addition, the lyophilized rabies vaccine obtained in the embodiment of the present invention has a white and loose appearance and good morphology; at the same time, the drug safety evaluation was carried out on mice, and the weight of the mice increased normally, and no abnormal performance was observed.
[0121] In summary, the present invention provides a rabies vaccine freeze-dried preparation and a preparation method thereof. The present invention can enhance the freeze-drying protection effect of the vaccine by using a first microwave power and a second microwave power to perform alternating microwave treatment in combination with a freeze-thaw method for cyclic treatment of the freeze-dried protection composition for several times, so that the prepared rabies vaccine freeze-dried preparation has the characteristics of intact appearance and good stability, thereby extending the shelf life of the vaccine, and providing a new means for the preparation of rabies vaccine freeze-dried preparations.
[0122] Various embodiments of the present invention may be presented in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present invention; therefore, the range description should be considered to have specifically disclosed all possible sub-ranges and single numerical values within the range. For example, the range description from 1 to 6 should be considered to have specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5 and 6, which apply regardless of the range. In addition, whenever a numerical range is indicated herein, it is meant to include any cited number (fractional or integer) within the indicated range.
[0123] The foregoing is merely a specific embodiment of the present invention, which enables those skilled in the art to understand or implement the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features claimed herein.
Claims
1. A method for preparing a rabies vaccine freeze-dried preparation, characterized in that: The rabies vaccine freeze-dried preparation comprises rabies vaccine stock solution and freeze-drying protective agent; In terms of weight percentage, the lyophilization protective agent includes the following components: 6.3% to 8.4% of freeze-dried protective composition, 0.7% to 1.1% of chloride salt, and the balance is phosphate buffer; The preparation method of the freeze-dried protective composition comprises the following steps: Step (1): adding trehalose, sucrose and dextran in a weight ratio of (1-2): (1-2): (2-4) into deionized water and stirring and mixing, and then performing microwave treatment alternately at a first microwave power and a second microwave power for 4-8 times, each microwave treatment lasting 20-50 seconds, to obtain a first mixed material; Step (2): freeze-thaw the first mixture to obtain a second mixture; Step (3): subjecting the second mixed material to the alternating microwave treatment in step (1) and the freeze-thaw treatment in step (2) in a cycle treatment cycle of 3 to 10 times, followed by drying and pulverization to obtain the freeze-dried protective composition; wherein the first microwave power is 60 to 100 W, and the second microwave power is 350 to 400 W; The preparation method of the rabies vaccine freeze-dried preparation comprises the following steps: Mixing the rabies vaccine stock solution and the lyophilization protective agent to obtain a semi-finished product; The semi-finished product is freeze-dried to obtain the rabies vaccine freeze-dried preparation.
2. The method for preparing the lyophilized rabies vaccine according to claim 1, characterized in that: The weight ratio of the trehalose, the sucrose and the dextran is 1:1.5:3, and the added weight of the deionized water accounts for 1 to 2 times the total weight of the trehalose, the sucrose and the dextran.
3. The method for preparing the lyophilized rabies vaccine preparation according to claim 1, characterized in that: The first microwave power is 75W, and the second microwave power is 380W.
4. The method for preparing the lyophilized rabies vaccine preparation according to claim 1, characterized in that: The chloride salt includes at least one of sodium chloride and magnesium chloride; the volume ratio of the rabies vaccine stock solution to the lyophilization protective agent is 1: (0.8~1.5).
5. The method for preparing the lyophilized rabies vaccine preparation according to claim 1, characterized in that: The freeze-thaw treatment includes freezing treatment and thawing treatment; The freezing treatment condition parameters include: first freezing at -50~-40°C for 3~4 hours, then vacuuming to 0.1~0.2 mbar and heating to -25~-20°C for second freezing for 12~18 hours; The thawing process condition parameters include: thawing to liquid at a temperature of 35-45°C.
6. The method for preparing the lyophilized rabies vaccine preparation according to claim 1, characterized in that: The rabies vaccine freeze-dried preparation includes a rabies vaccine freeze-dried preparation for oral use.
7. The method for preparing the lyophilized rabies vaccine preparation according to claim 5, characterized in that: The freeze-drying process includes pre-freezing process, main drying process and final drying process in sequence; The working condition parameters of the pre-freezing process are the same as the working condition parameters of the first freezing process; The working condition parameters of the main drying process are the same as the working condition parameters of the second freezing process.
8. The method for preparing the lyophilized rabies vaccine preparation according to claim 7, characterized in that: The condition parameters of the non-drying treatment include: heat preservation treatment at 25° C. for 5 to 8 hours.
Citation Information
Patent Citations
Novel rabies vaccine and preparation method thereof
CN103468743A
Rabies live vaccine and method for preparing rabies live vaccine for oral administration
CN103877570A
Rabies vaccine freeze drying preparation
CN108434106A
Recombinant chimpanzee source adenovirus for expressing rabies virus G protein and preparation method of recombinant chimpanzee source adenovirus
CN114591922A
Rabies vaccine freeze-drying protective agent, application, vaccine and preparation method of vaccine
CN115040656A
